Integrins and integrin-associated molecules: targets for the development of antimetastatic therapies
Velasco-Velázquez, M.A.; Molina-Guarneros, J.A.; Mendoza-Patiño, N.; Sullivan López, J.; Mandoki, J.J.
Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 51(3): 183-193
1999
ISSN/ISBN: 0034-8376 PMID: 10466009 Document Number: 500319
Integrins are receptors that mediate cell adhesion and the formation of signaling complex. Changes in the expression of integrins are required during the following steps in the generation of metastases: a) angiogenesis; b) detachment from the primary tumor; c) tumor cell-platelet interaction; d) adhesion to vascular endothelium and e) proliferation. There is a correlation between invasive capability and changes in the expression of some proteins that are clustered in focal adhesion sites, as FAK, CD82, CD9 or CD63. Both, integrin blocking (using antibodies or RGD containing peptides), as well as induced changes in the expression of integrin-associated molecules, are able to inhibit formation of metastases. Discovery and characterization of molecules that regulate the adhesive capability of tumor cells, will lead to development of antimetastasic therapies. In the search of tumor dissemination inhibitors, integrins and some integrin-associated molecules are important pharmacological targets.